Table q1_q4_2023_prescription_drug_wac

Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like U*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000090	UCB, Inc	03/31/2023	50474077066	BRIVIACT 100MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474077009	BRIVIACT 100MG UNIT DOSE CARTON OF 100 TABLETS	Brand	FDA	01/01/2023	127.70	2291.95	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474037066	BRIVIACT 10MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474087015	BRIVIACT 10MG ORAL SOLUTION-300ML	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474047066	BRIVIACT 25MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474047009	BRIVIACT 25MG UNIT DOSE CARTON OF 100 TABLETS	Brand	FDA	01/01/2023	127.70	2291.95	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474057066	BRIVIACT 50MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474057009	BRIVIACT 50MG UNIT DOSE CARTON OF 100 TABLETS	Brand	FDA	01/01/2023	127.70	2291.95	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474067066	BRIVIACT 75MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474097075	BRIVIACT IV INJECTION FOR INTRAVENOUS USE 50mg/5mL	Brand	FDA	01/01/2023	32.84	589.36	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474070062	CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS	Brand	FDA	01/01/2023	300.88	5400.56	02/13/2024	Single Source Drug	1451431000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474071079	CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES	Brand	FDA	01/01/2023	300.88	5400.56	02/13/2024	Single Source Drug	1451431000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474071081	CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES	Brand	FDA	01/01/2023	902.65	16201.68	02/13/2024	Single Source Drug	1451431000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059766	KEPPRA 1000MG-60 TABLETS	Brand	FDA	01/01/2023	63.17	1133.76	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059440	KEPPRA 250MG-120 TABLETS	Brand	FDA	01/01/2023	51.68	927.63	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059540	KEPPRA 500 MG-120 TABLETS	Brand	FDA	01/01/2023	63.17	1133.76	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059640	KEPPRA 750MG-120 TABLETS	Brand	FDA	01/01/2023	85.58	1536.02	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474000263	KEPPRA IV-1ML INJECTION FOR INTRAVENOUS USE 500mg5mL 10 VIALS	Brand	FDA	01/01/2023	35.49	636.96	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474000148	KEPPRA ORAL SOLUTION-100MG	Brand	FDA	01/01/2023	48.02	861.85	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059866	KEPPRA XR (LEVETIRACETAM) 500MG-60 TABLETS	Brand	FDA	01/01/2023	28.63	513.89	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059966	KEPPRA XR 750MG (LEVETIRACETAM)-60 TABLETS	Brand	FDA	01/01/2023	42.99	771.63	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247860	VIMPAT 100MG UD-60 TABLETS	Brand	FDA	01/01/2023	64.79	1163.02	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247835	VIMPAT 100MG-60 TABLETS	Brand	FDA	01/01/2023	58.90	1057.21	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247960	VIMPAT 150MG UD-60 TABLETS	Brand	FDA	01/01/2023	68.62	1231.70	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247935	VIMPAT 150MG-60 TABLETS	Brand	FDA	01/01/2023	62.38	1119.67	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131248060	VIMPAT 200MG UD-60 TABLETS	Brand	FDA	01/01/2023	68.64	1232.10	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131248035	VIMPAT 200MG-60 TABLETS	Brand	FDA	01/01/2023	62.40	1119.98	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247760	VIMPAT 50MG UD-60 TABLETS	Brand	FDA	01/01/2023	41.45	743.92	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247735	VIMPAT 50MG-60 TABLETS	Brand	FDA	01/01/2023	37.67	676.22	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131181067	VIMPAT INJECTION FOR INTRAVENOUS USE 200MG/20ML 10 VIALS	Brand	FDA	01/01/2023	51.54	925.03	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131541072	VIMPAT ORAL SOLUTION 10MG-200ML	Brand	FDA	01/01/2023	24.37	437.38	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794010201	Crysvita 10 mg/mL Subcutaneous Injection 1 Carton	Brand	FDA	01/02/2023	119.00	4116.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794020301	Crysvita 20 mg/mL Subcutaneous Injection 1 Carton	Brand	FDA	01/02/2023	238.00	8232.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794030401	Crysvita 30 mg/mL Subcutaneous Injection 1 Carton	Brand	FDA	01/02/2023	357.00	12348.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794000101	Mepsevii 10 mg/5mL (2mg/mL) Intravenous Injection 1 Carton	Brand	FDA	01/02/2023	74.00	2560.00	03/05/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000036	United Therapeutics	03/31/2023	66302030010	ORENITRAM ER .125 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	4.27	66.20	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302030001	ORENITRAM ER .125 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	42.73	661.98	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302030210	ORENITRAM ER .25 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	8.54	132.38	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302030201	ORENITRAM ER .25 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	85.45	1323.88	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302031010	ORENITRAM ER 1 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	34.18	529.57	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302031001	ORENITRAM ER 1 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	341.81	5295.65	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302032510	ORENITRAM ER 2.5 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	85.45	1323.91	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302032501	ORENITRAM ER 2.5 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	854.54	13239.15	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302035001	ORENITRAM ER 5 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	1709.07	26478.27	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302035010	ORENITRAM ER 5 MG Pack Oral Tablet 10 Pack	Brand	FDA	01/01/2023	170.91	2647.83	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302001401	Unituxin Intravenous Solution 17.5 MG/5ML 1 Vial in 1 Carton	Brand	FDA	01/01/2023	1420.61	15770.21	03/01/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.